BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding BioCardia, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 23 | 16 | −7 |
| Shares | 1.66M | 1.65M | −6.00K (−0.4%) |
| Value | $4.43M | $709.6K | −$3.72M (−84.0%) |
New holders (1)
Institutions that held BioCardia, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 10,502 | $4.00K | 0.00% |
Sold out (8)
Institutions that held BioCardia, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Lynwood Capital Management Inc. | 128,924 | $344.2K |
| Vontobel Holding Ltd. | 30,751 | $82.1K |
| Bank of New York Mellon Corp | 12,578 | $33.6K |
| Citadel Advisors LLC | 11,844 | $31.6K |
| Simplex Trading, LLC | 3,593 | $9.00K |
| UBS Group AG | 615 | $1.64K |
| Tower Research Capital LLC (TRC) | 143 | $382 |
| WealthPLAN Partners, LLC | 25 | $67 |